Tianjin Lisheng Pharmaceutical (SHE:002393) reported a net profit attributable to owners of 184.5 million yuan for the year 2024, down from 361.8 million yuan in the prior year.
Earnings per share fell to 0.72 yuan from 1.40 yuan a year ago, its parent company Tianjin Development Holdings (HKG:0882) said in a Friday filing with the Hong Kong bourse.
Total operating income, however, rose to 1.34 billion yuan from 1.15 billion yuan in the previous year.
The company proposed a 0.35 yuan per-share dividend, inclusive of taxes. The dividend is subject to approval by the shareholders.
Tianjin Lisheng's shares fell 3% in Shenzhen.
Price (HKD): $17.83, Change: $+0.15, Percent Change: +0.85%